Glasdegib has shown efficacy primarily in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). In clinical trials, glasdegib has been used in combination with low-dose cytarabine (LDAC) for the treatment of newly diagnosed AML in adult patients who are 75 years or older or who have comorbidities that preclude the use of intensive chemotherapy.